NoreenRothHenigMD
Pulmonology • San Francisco, CACritical Care Medicine
Sr. Director, Cardiopulmonary Medical Affairs
Dr. Henig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2351 Clay St
#501
San Francisco, CA 94115Phone+1 415-923-3421Fax+1 415-600-1414
Education & Training
University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1998
University of California (San Francisco)Residency, Internal Medicine, 1992 - 1995
Albert Einstein College of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1994 - 2026
Clinical Trials
- Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) Start of enrollment: 2020 Mar 12
Publications & Presentations
PubMed
- 133 citationsRisk factors for death of patients with cystic fibrosis awaiting lung transplantation.Richard A. Belkin, Noreen R. Henig, Lianne G. Singer, Cecilia Chaparro, Ronald C. Rubenstein
American Journal of Respiratory and Critical Care Medicine. 2006-03-15 - 144 citationsInflammatory and Microbiologic Markers in Induced Sputum after Intravenous Antibiotics in Cystic FibrosisClaudia L. Ordoñez, Noreen R. Henig, Nicole Mayer-Hamblett, Frank J. Accurso, Jane L. Burns
American Journal of Respiratory and Critical Care Medicine. 2003-12-15 - 105 citationsPulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restrictionGanesh Raghu, Steven D. Nathan, Juergen Behr, Kevin K. Brown, Jim J. Egan
The European Respiratory Journal. 2015-08-06
Press Mentions
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 1st, 2023- Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus NephritisJune 27th, 2022
- Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus NephritisNovember 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
